tetano
Editor, Senior Moderator
Front Immunol
. 2023 Jan 30;14:1077236.
doi: 10.3389/fimmu.2023.1077236. eCollection 2023.
Immune responses in mildly versus critically ill COVID-19 patients
Hamid Nasrollahi[SUP] 1 [/SUP], Atefe Ghamar Talepoor[SUP] 2 [/SUP], Zahra Saleh[SUP] 2 [/SUP], Mahsa Eshkevar Vakili[SUP] 2 [/SUP], Paria Heydarinezhad[SUP] 2 [/SUP], Narges Karami[SUP] 2 [/SUP], Maryam Noroozi[SUP] 2 [/SUP], Seppo Meri[SUP] 3 [/SUP], Kurosh Kalantar[SUP] 2 4 [/SUP]
Affiliations
Abstract
The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had devastating effects on the global health and economic system. The cellular and molecular mediators of both the innate and adaptive immune systems are critical in controlling SARS-CoV-2 infections. However, dysregulated inflammatory responses and imbalanced adaptive immunity may contribute to tissue destruction and pathogenesis of the disease. Important mechanisms in severe forms of COVID-19 include overproduction of inflammatory cytokines, impairment of type I IFN response, overactivation of neutrophils and macrophages, decreased frequencies of DC cells, NK cells and ILCs, complement activation, lymphopenia, Th1 and Treg hypoactivation, Th2 and Th17 hyperactivation, as well as decreased clonal diversity and dysregulated B lymphocyte function. Given the relationship between disease severity and an imbalanced immune system, scientists have been led to manipulate the immune system as a therapeutic approach. For example, anti-cytokine, cell, and IVIG therapies have received attention in the treatment of severe COVID-19. In this review, the role of immunity in the development and progression of COVID-19 is discussed, focusing on molecular and cellular aspects of the immune system in mild vs. severe forms of the disease. Moreover, some immune- based therapeutic approaches to COVID-19 are being investigated. Understanding key processes involved in the disease progression is critical in developing therapeutic agents and optimizing related strategies.
Keywords: COVID-19; SARS-CoV-2; T cells; antibodies; cytokine storm; immune response; inflammation; therapeutic targets.
. 2023 Jan 30;14:1077236.
doi: 10.3389/fimmu.2023.1077236. eCollection 2023.
Immune responses in mildly versus critically ill COVID-19 patients
Hamid Nasrollahi[SUP] 1 [/SUP], Atefe Ghamar Talepoor[SUP] 2 [/SUP], Zahra Saleh[SUP] 2 [/SUP], Mahsa Eshkevar Vakili[SUP] 2 [/SUP], Paria Heydarinezhad[SUP] 2 [/SUP], Narges Karami[SUP] 2 [/SUP], Maryam Noroozi[SUP] 2 [/SUP], Seppo Meri[SUP] 3 [/SUP], Kurosh Kalantar[SUP] 2 4 [/SUP]
Affiliations
- PMID: 36793739
- PMCID: PMC9923185
- DOI: 10.3389/fimmu.2023.1077236
Abstract
The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had devastating effects on the global health and economic system. The cellular and molecular mediators of both the innate and adaptive immune systems are critical in controlling SARS-CoV-2 infections. However, dysregulated inflammatory responses and imbalanced adaptive immunity may contribute to tissue destruction and pathogenesis of the disease. Important mechanisms in severe forms of COVID-19 include overproduction of inflammatory cytokines, impairment of type I IFN response, overactivation of neutrophils and macrophages, decreased frequencies of DC cells, NK cells and ILCs, complement activation, lymphopenia, Th1 and Treg hypoactivation, Th2 and Th17 hyperactivation, as well as decreased clonal diversity and dysregulated B lymphocyte function. Given the relationship between disease severity and an imbalanced immune system, scientists have been led to manipulate the immune system as a therapeutic approach. For example, anti-cytokine, cell, and IVIG therapies have received attention in the treatment of severe COVID-19. In this review, the role of immunity in the development and progression of COVID-19 is discussed, focusing on molecular and cellular aspects of the immune system in mild vs. severe forms of the disease. Moreover, some immune- based therapeutic approaches to COVID-19 are being investigated. Understanding key processes involved in the disease progression is critical in developing therapeutic agents and optimizing related strategies.
Keywords: COVID-19; SARS-CoV-2; T cells; antibodies; cytokine storm; immune response; inflammation; therapeutic targets.